The Manufacturers Life Insurance Company Buys 657 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

The Manufacturers Life Insurance Company boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 3.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,473 shares of the company’s stock after purchasing an additional 657 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.06% of TransMedics Group worth $2,900,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. International Assets Investment Management LLC bought a new position in shares of TransMedics Group in the second quarter valued at approximately $47,000. USA Financial Formulas purchased a new stake in TransMedics Group in the 3rd quarter worth approximately $55,000. J.Safra Asset Management Corp boosted its holdings in TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC grew its position in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Canaccord Genuity Group dropped their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Piper Sandler cut their price objective on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, TD Cowen cut their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $68.26 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 52-week low of $66.10 and a 52-week high of $177.37. The company has a fifty day moving average of $103.61 and a 200-day moving average of $133.90. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of 72.62 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period last year, the business posted ($0.12) earnings per share. Equities research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling

In other news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. This represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,042 shares of company stock worth $3,563,985 in the last ninety days. 7.00% of the stock is owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.